Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?

Abstract

New emerging drugs in the treatment of ankylosing spondylitis (AS), and spondyloarthritis in general, should be compared to anti-TNF agents, which provided clear evidence of efficacy in these conditions. To date, other biologic agents used in rheumatoid arthritis failed to demonstrate efficacy in AS, even in anti-TNF naïve patients. Some new potential options may target cytokines such as IL-17, or molecules involved in entheseal ossification or signaling pathways, but need confirmatory evaluation.

Keywords::

• ankylosing spondylitis
• anti-TNF agents
• IL-17
• IL-23
• spondyloarthritis
• treatment